MIA抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P10244(MIA Antibody) at dilution 1/100. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P10244(MIA Antibody) at dilution 1/100. (Original magnification: ×200)    

  
  

Melanoma inhibitory activity (MIA) antibody is a tool used to detect MIA, a small secreted protein (12 kDa) initially identified in the 1990s for its role in inhibiting melanoma cell proliferation and metastasis. MIA is primarily expressed in malignant melanoma and chondrocytes, playing a dual role in tumor progression. It promotes cancer cell invasion and migration by modulating extracellular matrix interactions and integrin signaling, while also exhibiting context-dependent anti-proliferative effects. Structurally, MIA belongs to the SH3 domain-containing protein family and is transcriptionally regulated by factors like MITF in melanoma.

Elevated MIA levels in serum correlate with advanced melanoma stages and poor prognosis, making it a biomarker for monitoring metastasis and treatment response. Beyond melanoma, MIA overexpression is observed in chondrosarcoma, glioblastoma, and breast cancer. Antibodies against MIA are used in ELISA, immunohistochemistry, and Western blotting for research and diagnostic purposes. Recent studies explore MIA as a therapeutic target, with neutralizing antibodies investigated for blocking tumor-stroma interactions. However, its pleiotropic functions in cartilage development and neurodegeneration necessitate cautious therapeutic exploitation. MIA antibodies thus remain pivotal in unraveling its complex biology and clinical applications.